HB0025 + paclitaxel + carboplatin

HB0025 + paclitaxel + carboplatin is an investigational combination therapy for advanced solid tumors, particularly being evaluated in clinical trials for non-squamous non-small cell lung cancer and advanced endometrial carcinoma. The regimen combines HB0025, a recombinant humanized bispecific fusion protein antibody targeting both programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF), with paclitaxel (a microtubule inhibitor antineoplastic agent) and carboplatin (a platinum-based DNA-damaging chemotherapeutic). The therapeutic rationale is to inhibit immune escape via PD-L1 blockade, suppress tumor angiogenesis via VEGF inhibition, and apply cytotoxic effects from paclitaxel and carboplatin, aiming for synergistic antitumor activity[1][3][5][7].